|
1
|
Gui H, Tong Q, Qu W, Mao CM and Dai SM:
The endocannabinoid system and its therapeutic implications in
rheumatoid arthritis. Int Immunopharmacol. 26:86–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kano M, Ohno-Shosaku T, Hashimotodani Y,
Uchigashima M and Watanabe M: Endocannabinoid-mediated control of
synaptic transmission. Physiol Rev. 89:309–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ligresti A, De Petrocellis L and Di Marzo
V: From phytocannabinoids to cannabinoid receptors and
endocannabinoids: Pleiotropic physiological and pathological roles
through complex pharmacology. Physiol Rev. 96:1593–1659. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cabral GA and Griffin-Thomas L:
Cannabinoids as therapeutic agents for ablating neuroinflammatory
disease. Endocr Metab Immune Disord Drug Targets. 8:159–172. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cabral GA, Rogers TJ and Lichtman AH:
Turning over a new leaf: Cannabinoid and endocannabinoid modulation
of immune function. J Neuroimmune Pharmacol. 10:193–203. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Centonze D, Finazzi-Agrò A, Bernardi G and
Maccarrone M: The endocannabinoid system in targeting inflammatory
neurodegenerative diseases. Trends Pharmacol Sci. 28:180–187. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Echigo R, Sugimoto N, Yachie A and
Ohno-Shosaku T: Cannabinoids inhibit peptidoglycan-induced
phosphorylation of NF-κB and cell growth in U87MG human malignant
glioma cells. Oncol Rep. 28:1176–1180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guindon J and Hohmann AG: The
endocannabinoid system and cancer: Therapeutic implication. Br J
Pharmacol. 163:1447–1463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salazar M, Carracedo A, Salanueva IJ,
Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C,
Torres S, García S, et al: Cannabinoid action induces
autophagy-mediated cell death through stimulation of ER stress in
human glioma cells. J Clin Invest. 119:1359–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh R, Singh B and Malhotra SK: A new
‘marker’ protein for astrocytes. Biosci Rep. 6:73–80. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dell'albani P, Rodolico M, Pellitteri R,
Tricarichi E, Torrisi SA, D'Antoni S, Zappia M, Albanese V,
Caltabiano R, Platania N, et al: Differential patterns of NOTCH1-4
receptor expression are markers of glioma cell differentiation.
Neuro Oncol. 16:204–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burnet NG, Lynch AG, Jefferies SJ, Price
SJ, Jones PH, Antoun NM, Xuereb JH and Pohl U: High grade glioma:
Imaging combined with pathological grade defines management and
predicts prognosis. Radiother Oncol. 85:371–378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daumas-Duport C, Scheithauer B, O'Fallon J
and Kelly P: Grading of astrocytomas. A simple and reproducible
method. Cancer. 62:2152–2165. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gurley SN, Abidi AH, Allison P, Guan P,
Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger
AJ, et al: Mechanism of anti-glioma activity and in vivo efficacy
of the cannabinoid ligand KM-233. J Neurooncol. 110:163–177. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ortega A, Rangel-López E, Hidalgo-Miranda
A, Morales A, Ruiz-García E, Meneses-García A, Herrera-Gómez A,
Aguilar-Ponce JL, González-Herrera IG, Guevara-Salazar P, et al: On
the effects of CP 55–940 and other cannabinoid receptor agonists in
C6 and U373 cell lines. Toxicol In Vitro. 29:1941–1951. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horiuchi A, Imai T, Shimizu M, Oka K, Wang
C, Nikaido T and Konishi I: Hypoxia-induced changes in the
expression of VEGF, HIF-1 alpha and cell cycle-related molecules in
ovarian cancer cells. Anticancer Res. 22:2697–2702. 2002.PubMed/NCBI
|
|
18
|
Bao B, Azmi AS, Ali S, Ahmad A, Li Y,
Banerjee S, Kong D and Sarkar FH: The biological kinship of hypoxia
with CSC and EMT and their relationship with deregulated expression
of miRNAs and tumor aggressiveness. Biochim Biophys Acta.
1826:272–296. 2012.PubMed/NCBI
|
|
19
|
Kawai N, Maeda Y, Kudomi N, Miyake K,
Okada M, Yamamoto Y, Nishiyama Y and Tamiya T: Correlation of
biological aggressiveness assessed by 11C-methionine PET
and hypoxic burden assessed by 18F-fluoromisonidazole
PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging.
38:441–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alhouayek M and Muccioli GG: COX-2-derived
endocannabinoid metabolites as novel inflammatory mediators. Trends
Pharmacol Sci. 35:284–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hermanson DJ, Gamble-George JC, Marnett LJ
and Patel S: Substrate-selective COX-2 inhibition as a novel
strategy for therapeutic endocannabinoid augmentation. Trends
Pharmacol Sci. 35:358–367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCarthy KD and de Vellis J: Preparation
of separate astroglial and oligodendroglial cell cultures from rat
cerebral tissue. J Cell Biol. 85:890–902. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohno-Shosaku T, Maejima T and Kano M:
Endogenous cannabinoids mediate retrograde signals from depolarized
postsynaptic neurons to presynaptic terminals. Neuron. 29:729–738.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sugimoto N, Leu H, Inoue N, Shimizu M,
Toma T, Kuroda M, Saito T, Wada T and Yachie A: The critical role
of lipopolysaccharide in the upregulation of aquaporin 4 in glial
cells treated with Shiga toxin. J Biomed Sci. 22:782015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leu H, Sugimoto N, Shimizu M, Toma T, Wada
T, Ohta K and Yachie A: Tumor necrosis factor-α modifies the
effects of Shiga toxin on glial cells. Int Immunopharmacol.
38:139–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mongiardi MP: Angiogenesis and hypoxia in
glioblastoma: A focus on cancer stem cells. CNS Neurol Disord Drug
Targets. 11:878–883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang S, Liu Z, Wang L and Zhang X:
NF-kappaB signaling pathway, inflammation and colorectal cancer.
Cell Mol Immunol. 6:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Friedmann-Morvinski D: Glioblastoma
heterogeneity and cancer cell plasticity. Crit Rev Oncog.
19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sowers JL, Johnson KM, Conrad C, Patterson
JT and Sowers LC: The role of inflammation in brain cancer. Adv Exp
Med Biol. 816:75–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sugimoto N, Shido O, Matsuzaki K, Katakura
M, Hitomi Y, Tanaka M, Sawaki T, Fujita Y, Kawanami T, Masaki Y, et
al: Long-term heat exposure prevents hypoxia-induced apoptosis in
mouse fibroblast cells. Cell Biochem Biophys. 70:301–307. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugimoto N, Takuwa N, Yoshioka K and
Takuwa Y: Rho-dependent, Rho kinase-independent inhibitory
regulation of Rac and cell migration by LPA1 receptor in
Gi-inactivated CHO cells. Exp Cell Res. 312:1899–1908. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klein TW: Cannabinoid-based drugs as
anti-inflammatory therapeutics. Nat Rev Immunol. 5:400–411. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guzmán M: Cannabinoids: Potential
anticancer agents. Nat Rev Cancer. 3:745–755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sarfaraz S, Adhami VM, Syed DN, Afaq F and
Mukhtar H: Cannabinoids for cancer treatment: Progress and promise.
Cancer Res. 68:339–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zoerner AA, Gutzki FM, Batkai S, May M,
Rakers C, Engeli S, Jordan J and Tsikas D: Quantification of
endocannabinoids in biological systems by chromatography and mass
spectrometry: A comprehensive review from an analytical and
biological perspective. Biochim Biophys Acta. 1811:706–723. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blázquez C, Salazar M, Carracedo A,
Lorente M, Egia A, González-Feria L, Haro A, Velasco G and Guzmán
M: Cannabinoids inhibit glioma cell invasion by down-regulating
matrix metalloproteinase-2 expression. Cancer Res. 68:1945–1952.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rocha FC, Dos Santos Júnior JG, Stefano SC
and da Silveira DX: Systematic review of the literature on clinical
and experimental trials on the antitumor effects of cannabinoids in
gliomas. J Neurooncol. 116:11–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
De Jesús ML, Hostalot C, Garibi JM, Sallés
J, Meana JJ and Callado LF: Opposite changes in cannabinoid CB1 and
CB2 receptor expression in human gliomas. Neurochem Int.
56:829–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ono M: Molecular links between tumor
angiogenesis and inflammation: Inflammatory stimuli of macrophages
and cancer cells as targets for therapeutic strategy. Cancer Sci.
99:1501–1506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dai C and Holland EC: Astrocyte
differentiation states and glioma formation. Cancer J. 9:72–81.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Muz B, de la Puente P, Azab F and Azab AK:
The role of hypoxia in cancer progression, angiogenesis,
metastasis, and resistance to therapy. Hypoxia. 3:83–92. 2015.
View Article : Google Scholar : PubMed/NCBI
|
